You are here: Industry Insights > COVID-19

News List

Berlin, other German states offer COVID-19 vaccine to 5-11s FirstWordPharma
December 13, 2021
Health officials said on Sunday that children aged from five to 11 years will be eligible to begin receiving COVID-19 vaccine doses this week in Berlin, as reported ABC News.
NHS waiting times reach record high of nearly six million PharmaTimes
December 13, 2021
In October 2021, over 356,000 people in England had been waiting for over six weeks for a key diagnostic test.
European Commission approves Actemra/RoActemra by Roche to treat severe COVID-19 expresspharma
December 13, 2021
Approval based on results from four phase-III studies in more than 5,500 patients
Health minister welcomes new treatments for COVID-19 patients PharmaTimes
December 13, 2021
The treatments are being offered as an addition to vaccinations to maximise protection against COVID-19.
Aldatu's SARS-CoV-2 Variant Genotyping Test differentiates between Omicron, Delta, and all other variants of concern. prnewswire
December 13, 2021
Aldatu Biosciences (Watertown, MA) has confirmed that their PANDAA qDx SARS-CoVar (Variant Genotyping) Test Kit enables detection and allelic discrimination of variant lineage-defininig mutations.
FDA Issues Emergency Use Authorization for AstraZeneca’s EVUSHELD? (tixagevimab co-packaged with cilgavimab), the First Antibody Therapy Authorized in the U.S. for Pre-Exposure Prophylaxis of COVID-19 prnewswire
December 13, 2021
Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD? and assisting with the development of the nonproprietary names tixagevimab...
Aerogen and CanSinoBIO to partner for inhaled delivery of Covid-19 vaccine Pharmaceutical-Technology
December 13, 2021
CanSinoBIO has signed a development and commercial supply collaboration with Ireland based company Aerogen for the inhaled recombinant Covid-19 vaccine, Convidecia.
US FDA grants EUA to AstraZeneca’s Evusheld in US for pre-exposure prophylaxis of COVID-19 expresspharma
December 10, 2021
Phase-III data showed at least six months of protection with one dose in high-risk participant population
Evusheld (Formerly AZD7442) Long-Acting Antibody Combination Authorized For Emergency Use In The US For Prevention of COVID-19 AmericanPharmaceuticalReview
December 10, 2021
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected...
EMA recommends RoActemra in adults with severe COVID-19 EuropeanPharmaceuticalReview
December 10, 2021
The European Medicines Agency (EMA)’s human medicines committee (CHMP) recommends extending RoActemra’s indication to include COVID-19 patients receiving systemic treatment.